Mivacurium and bronchospasm.
Because of case reports of severe bronchospasm after the use of mivacurium, we used the Food and Drug Administration MedWatch database to determine the frequency of bronchospasm as an adverse event after the use of nondepolarizing muscle relaxants.
Bishop
Michael J
MJ
*Department of Anesthesiology, University of Washington, Seattle, Washington; †Department of Pharmacology, Rush Medical College, Chicago; and ‡Pharmaconsultant, Inc., Palatine, Illinois.
O'Donnell
J T
JT
Salemi
J R
JR
D000293:Adolescent; D001986:Bronchial Spasm / Q000139:chemically induced*; D002648:Child; D005260:Female; D006801:Humans; D007546:Isoquinolines / Q000009:adverse effects*; D008297:Male; D000077590:Mivacurium; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects*
D007546:Isoquinolines; D003473:Neuromuscular Nondepolarizing Agents; D000077590:Mivacurium